TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32278280

Group type: EXPERIMENTAL
Intervention: DEB-TACE using tightly calibrated 100-μm microspheres loaded with 50 mg of doxorubicin per millilitre
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: DEB-TACE
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Doxorubicin dose
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Co-morbidities and tumour response
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Complications
Number of subjects: 131
Study: 32278355

Group type: EXPERIMENTAL
Intervention: Sport specialists (moderate to vigorous physical activity)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Non-sport specialists (any activity level)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Participants diagnosed with FAI
Number of subjects: 200

Group type: COMPARATOR
Intervention: Participants without FAI
Number of subjects: 200
Study: 32278382

Group type: EXPERIMENTAL
Intervention: PS gene editing system using adeno-associated virus 8 (AAV8) vectors
Number of subjects: 0
Study: 32278621

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy (200-mg run-in dose followed by eight cycles of pembrolizumab with a taxane with or without carboplatin for 12 weeks, then doxorubicin and cyclophosphamide for an additional 12 weeks)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy
Number of subjects: 60
Study: 32279228

Group type: EXPERIMENTAL
Intervention: Bosutinib 400 mg once daily (QD)
Number of subjects: 60
Study: 32279360

Group type: EXPERIMENTAL
Intervention: Chair resistance training (RT) with sandbags/dumbbells, twice a week for 3 months
Number of subjects: 123

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 123
Study: 32279621

Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin T (hs-cTnT) quartiles
Number of subjects: 555
Study: 32279704

Group type: EXPERIMENTAL
Intervention: Weekend catch-up sleep of more than 1 hour for children who slept ≥ 9 hours on weekdays
Number of subjects: 4699

Group type: EXPERIMENTAL
Intervention: Weekday sleep duration < 9 hours
Number of subjects: 4699

Group type: EXPERIMENTAL
Intervention: Weekend catch-up sleep
Number of subjects: 4699

Group type: EXPERIMENTAL
Intervention: Weekend catch-up sleep over 1 hour
Number of subjects: 4699
Study: 32279702

Group type: COMPARATOR
Intervention: Primary care diagnostic agreement
Number of subjects: 229

Group type: COMPARATOR
Intervention: Therapeutic decisions (PAP vs conservative treatment)
Number of subjects: 229

Group type: COMPARATOR
Intervention: Therapeutic decisions excluding indeterminate options
Number of subjects: 229

Group type: COMPARATOR
Intervention: Final therapeutic decisions made at sleep unit
Number of subjects: 229
Study: 32280086

Group type: EXPERIMENTAL
Intervention: Caregiver surveys every four months for two years or until the PWSD passes away, followed by assessments at eight weeks and six months post-death.
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Validated tools to assess PWSDs' quality of life, suffering, behaviors, functional status, resource utilization.
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Qualitative in-depth interviews with a sub-sample of caregivers.
Number of subjects: 250
Study: 32280263

Group type: EXPERIMENTAL
Intervention: Naldemedine 0.2 mg
Number of subjects: 2328

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2328
Study: 32280268

Group type: EXPERIMENTAL
Intervention: Morphine group (M): received ultrasound-guided serratus anterior plane block with 20 mL of bupivacaine hydrochloride 0.25% plus 10 mg morphine sulfate
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (C): received ultrasound-guided serratus anterior plane block with 20 mL of bupivacaine hydrochloride 0.25%
Number of subjects: 40
Study: 32280375

Group type: EXPERIMENTAL
Intervention: Combination of prebiotics and probiotics
Number of subjects: 8
Study: 32280513

Group type: EXPERIMENTAL
Intervention: Digital exophthalmometry measurements (24.32 ± 5.17 mm for proptosis group; 18.62 ± 3.87 mm for normal group)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Hertel exophthalmometry (HE) measurements (20.87 ± 2.53 mm for proptosis group; 17.52 ± 2.67 mm for normal group)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: CT measurements
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Clinical measurements
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Digital measurements
Number of subjects: 32

Group type: COMPARATOR
Intervention: HE vs CT correlation
Number of subjects: 32
Study: 32280517

Group type: EXPERIMENTAL
Intervention: VHZI via anterior chamber approach
Number of subjects: 9

Group type: COMPARATOR
Intervention: VHZI via pars plana approach
Number of subjects: 9
Study: 32280529

Group type: EXPERIMENTAL
Intervention: Cataract surgery in eyes with persistent fetal vasculature (PFV)
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Cataract surgery in eyes with posterior capsule defect (PCD)
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Cataract surgery in eyes with posterior lenticonus (PLC)
Number of subjects: 239

Group type: COMPARATOR
Intervention: Cataract surgery in eyes without posterior capsule abnormalities (PCA)
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Cataract surgery in PCA patients
Number of subjects: 239
Study: 32280821

Group type: EXPERIMENTAL
Intervention: DIL-SIB (dominant intraprostatic lesion simultaneous in-field boosts)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: PSMA PET (18F-DCFPyL)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Comparative DIL-SIB plans
Number of subjects: 6
Study: 32281541

Group type: EXPERIMENTAL
Intervention: ACT OUT! Social Issue Theater program (3 moderated psychodramatic performances by trained actors)
Number of subjects: 1594

Group type: COMPARATOR
Intervention: Usual school day (control condition)
Number of subjects: 1594
Study: 32281959

Group type: EXPERIMENTAL
Intervention: HFpEF with atrial fibrillation (AF)
Number of subjects: 819

Group type: COMPARATOR
Intervention: HFpEF with sinus rhythm (SR)
Number of subjects: 819
Study: 32282335

Group type: EXPERIMENTAL
Intervention: Light-to-moderate alcohol consumption (LMAC) in NAFLD-free participants
Number of subjects: 7079

Group type: COMPARATOR
Intervention: Nondrinking patients with NAFLD
Number of subjects: 7079

Group type: EXPERIMENTAL
Intervention: Light-drinking patients with NAFLD
Number of subjects: 7079

Group type: EXPERIMENTAL
Intervention: Moderate-drinking patients with NAFLD
Number of subjects: 7079
Study: 32282545

Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Good adherence to repeated FMT
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Laboratory preparation process
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Partial Mayo score at 1-month post-FMT
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: FMT
Number of subjects: 176
Study: 32282612

Group type: EXPERIMENTAL
Intervention: First 1,000 Days program (intervention); includes enhanced gestational weight gain tracking and counseling, screening for adverse health behaviors, patient navigation, educational materials, and individualized health coaching.
Number of subjects: 1571

Group type: EXPERIMENTAL
Intervention: First 1,000 Days program (intervention); among women who were overweight at the start of pregnancy.
Number of subjects: 1571

Group type: EXPERIMENTAL
Intervention: First 1,000 Days program (intervention); among women with prepregnancy BMIs of 30 or higher.
Number of subjects: 1571
Study: 32282661

Group type: EXPERIMENTAL
Intervention: Multicolor confocal scanning laser ophthalmoscopy (cSLO)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Swept source optical coherence tomography (as reference)
Number of subjects: 30
Study: 32282808

Group type: EXPERIMENTAL
Intervention: targeted provider-initiated testing and counselling (tPITC)
Number of subjects: 1990
Study: 32283280

Group type: EXPERIMENTAL
Intervention: Self-reported evaluation of sleep on a 0-10 numerical scale (PSAID-12)
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: Self-reported levels of anxiety
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: Self-reported levels of pain
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: Inflammation
Number of subjects: 396
Study: 32283326

Group type: EXPERIMENTAL
Intervention: NIR-ICG imaging after conservative ureteral procedures
Number of subjects: 31
Study: 32283645

Group type: EXPERIMENTAL
Intervention: Probiotic multi-strain formulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32284075

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 0
Study: 32284274

Group type: EXPERIMENTAL
Intervention: MenACWY-TT
Number of subjects: 184

Group type: COMPARATOR
Intervention: MenC-CRM
Number of subjects: 184
Study: 32284384

Group type: EXPERIMENTAL
Intervention: Gepotidacin (GSK2140944), dosage and duration not specified
Number of subjects: 0
Study: 32284391

Group type: EXPERIMENTAL
Intervention: EarlySense device
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Sibel device
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Verification and accuracy evaluation phase
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Clinical feasibility evaluation phase
Number of subjects: 500
Study: 32284874

Group type: EXPERIMENTAL
Intervention: Fingolimod (high exposure, ≥8 years)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Fingolimod (low exposure, <8 years)
Number of subjects: 175
Study: 32284945

Group type: EXPERIMENTAL
Intervention: Activity modification and knee-strengthening exercises
Number of subjects: 51
Study: 32285088

Group type: EXPERIMENTAL
Intervention: Mindful yoga intervention (1 hour, thrice weekly for 3 months)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 31
Study: 32285107

Group type: EXPERIMENTAL
Intervention: McKeown oesophagectomy
Number of subjects: 1540

Group type: COMPARATOR
Intervention: Ivor Lewis oesophagectomy
Number of subjects: 1540
Study: 32285130

Group type: EXPERIMENTAL
Intervention: Modified Low Back Pain Disability Questionnaire (MDQ)
Number of subjects: 182276

Group type: EXPERIMENTAL
Intervention: Neck Disability Index (NDI)
Number of subjects: 182276
Study: 32285143

Group type: EXPERIMENTAL
Intervention: GAP (Glasgow Coma Scale, Age and Pressure)
Number of subjects: 2112

Group type: EXPERIMENTAL
Intervention: MGAP (mechanism + GAP)
Number of subjects: 2112

Group type: EXPERIMENTAL
Intervention: RISC2
Number of subjects: 2112

Group type: EXPERIMENTAL
Intervention: (M)GAP scores
Number of subjects: 2112

Group type: EXPERIMENTAL
Intervention: GAP
Number of subjects: 2112
Study: 32285251

Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea (OSA) group
Number of subjects: 62

Group type: COMPARATOR
Intervention: No obstructive sleep apnea (no-OSA) group
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Both OSA and no-OSA groups
Number of subjects: 62
Study: 32285318

Group type: EXPERIMENTAL
Intervention: Random forest full model
Number of subjects: 3469

Group type: EXPERIMENTAL
Intervention: Random forest reduced model
Number of subjects: 3469

Group type: COMPARATOR
Intervention: Mehran risk score model
Number of subjects: 3469
Study: 32285998

Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA) at 15 mg/kg/day during radiation therapy and continued post-radiation, followed by bevacizumab at 10 mg/kg biweekly after radiation.
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA) and bevacizumab after radiation therapy.
Number of subjects: 38
Study: 32286195

Group type: EXPERIMENTAL
Intervention: Low-dose CT screening for lung cancer using Lung-RADS categories 3 or 4.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lung-RADS diagnostic performance in predicting lung cancer.
Number of subjects: 0
Study: 32286862

Group type: EXPERIMENTAL
Intervention: Plasma aldosterone levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atrial mitochondrial functions
Number of subjects: 0
Study: 32286905

Group type: EXPERIMENTAL
Intervention: CD22-targeted CAR T cells
Number of subjects: 58
Study: 32287122

Group type: EXPERIMENTAL
Intervention: Machine-learning algorithm (SVM) using RIP sensor
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Machine-learning algorithm (SVM) using intranasal pressure sensor
Number of subjects: 26

Group type: COMPARATOR
Intervention: Domain experts
Number of subjects: 26
Study: 32287128

Group type: EXPERIMENTAL
Intervention: Deep learning model trained on sleep EEG data using dexmedetomidine as a prototype drug
Number of subjects: 30
Study: 32287129

Group type: EXPERIMENTAL
Intervention: optical blood pressure monitoring (oBPM)
Number of subjects: 40
Study: 32289043

Group type: EXPERIMENTAL
Intervention: Laboratory-confirmed influenza diagnosis
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Other respiratory viruses
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Co-infection with influenza and other respiratory viruses
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Influenza virus types
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Direct medical costs associated with laboratory-confirmed influenza
Number of subjects: 501
Study: 32289161

Group type: EXPERIMENTAL
Intervention: Albuminuria (ACR ≥30 mg/g) for ≥2 annual measurements classified as persistent albuminuria (PA).
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Albuminuria progression with age.
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Persistent albuminuria (PA).
Number of subjects: 303

Group type: COMPARATOR
Intervention: Participants with PA compared to those without PA.
Number of subjects: 303

Group type: COMPARATOR
Intervention: Adults with albuminuria compared to those without albuminuria.
Number of subjects: 303
Study: 32289205

Group type: EXPERIMENTAL
Intervention: Fresh embryo transfer IVF
Number of subjects: 902891

Group type: COMPARATOR
Intervention: Frozen-thawed embryo transfer IVF
Number of subjects: 902891

Group type: COMPARATOR
Intervention: Natural conception
Number of subjects: 902891
Study: 32289718

Group type: EXPERIMENTAL
Intervention: Single-pulse TMS
Number of subjects: 2
Study: 32290822

Group type: EXPERIMENTAL
Intervention: Multi-component intervention aimed at improving personal and environmental hygiene among primary school children.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pre-intervention phase survey and qualitative exploration.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Post-intervention assessment using paired t-test.
Number of subjects: 0
Study: 32290833

Group type: EXPERIMENTAL
Intervention: Multiplex PCR (mPCR) for detection of antimicrobial resistance
Number of subjects: 94
Study: 32290838

Group type: EXPERIMENTAL
Intervention: Triptorelin SR (11.25 mg) plus Tibolone (2.5 mg)
Number of subjects: 27
Study: 32291090

Group type: EXPERIMENTAL
Intervention: Surgically corrected VSD patients
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Patients with small, unrepaired VSD
Number of subjects: 120

Group type: COMPARATOR
Intervention: Healthy age- and gender-matched controls
Number of subjects: 120
Study: 32291269

Group type: EXPERIMENTAL
Intervention: Tin protoporphyrin (SnPP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SnPP
Number of subjects: 0
Study: 32291308

Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC) for 1 hour
Number of subjects: 27

Group type: COMPARATOR
Intervention: Noninvasive ventilation (NIV)
Number of subjects: 27
Study: 32291564

Group type: EXPERIMENTAL
Intervention: Childhood cancer survivors
Number of subjects: 472

Group type: COMPARATOR
Intervention: IFPS II controls
Number of subjects: 472
Study: 32291773

Group type: EXPERIMENTAL
Intervention: Ultrasound-derived muscle thickness at mid-upper arm and bilateral thighs, including age, sex, and the Charlson Comorbidity Index.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Ultrasound-derived muscle thickness at each landmark.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Ultrasound prediction models.
Number of subjects: 50
Study: 32291833

Group type: EXPERIMENTAL
Intervention: Gender minority students (transgender, genderqueer/non-binary)
Number of subjects: 41412

Group type: EXPERIMENTAL
Intervention: Sexual minority subgroups (pansexual, bisexual, queer, mostly gay/lesbian)
Number of subjects: 41412

Group type: EXPERIMENTAL
Intervention: Pansexual students
Number of subjects: 41412

Group type: COMPARATOR
Intervention: Cisgender peers
Number of subjects: 41412

Group type: COMPARATOR
Intervention: Heterosexuals
Number of subjects: 41412
Study: 32293279

Group type: EXPERIMENTAL
Intervention: In-office insertion of the BioMonitor 2
Number of subjects: 82
Study: 32293300

Group type: EXPERIMENTAL
Intervention: Plasma levels of IL-17 and IL-23 at 2 or 7 days post ROSC
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Plasma levels of IL-17 and IL-23
Number of subjects: 21

Group type: COMPARATOR
Intervention: Plasma creatinine levels, AST and ALT levels
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Plasma levels of IL-17, IL-22, IL-23 and IL-33
Number of subjects: 21
Study: 32293348

Group type: EXPERIMENTAL
Intervention: Prenatal and perinatal conditions, genetic and epigenetic factors, immunophenotyping, evaluation of allergy biomarkers in cord blood.
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Maternal conditions and epigenetic modifications.
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Composition/diversity of maternal gut, placenta, breastmilk, and infant gut microbiome.
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Environmental exposures (perinatal outdoor and indoor pollution, allergens, and endotoxin).
Number of subjects: 250
Study: 32293352

Group type: EXPERIMENTAL
Intervention: Chemotherapy treatment
Number of subjects: 0
Study: 32293449

Group type: EXPERIMENTAL
Intervention: NT-proBNP > 88.64 pg/mL
Number of subjects: 54

Group type: COMPARATOR
Intervention: NT-proBNP ≤ 88.64 pg/mL
Number of subjects: 54
Study: 32293471

Group type: EXPERIMENTAL
Intervention: Whey protein supplementation
Number of subjects: 58

Group type: COMPARATOR
Intervention: Isocaloric carbohydrate beverage
Number of subjects: 58

Group type: COMPARATOR
Intervention: Water
Number of subjects: 58
Study: 32293504

Group type: EXPERIMENTAL
Intervention: Maternal dietary habits/physical activity (T1-T3)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Birth mode (cesarean section vs. vaginal delivery)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Maternal pre-pregnancy BMI (BMI < 25 Kg/m)
Number of subjects: 60
Study: 32293506

Group type: EXPERIMENTAL
Intervention: PEEP set at 15 or 20 cmH2O
Number of subjects: 12
Study: 32293568

Group type: EXPERIMENTAL
Intervention: Automated smartphone-based financial incentives for smoking cessation (up to US $250 over 12 weeks)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Automated smartphone-based financial incentives for smoking cessation
Number of subjects: 16
Study: 32293574

Group type: EXPERIMENTAL
Intervention: WeChat self-monitoring
Number of subjects: 258

Group type: COMPARATOR
Intervention: Traditional monitoring
Number of subjects: 258
Study: 32293641

Group type: EXPERIMENTAL
Intervention: Ixekizumab
Number of subjects: 12
Study: 32293940

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 32294529

Group type: EXPERIMENTAL
Intervention: Immunoscore Low (IS Low)
Number of subjects: 1322

Group type: EXPERIMENTAL
Intervention: Immunoscore Intermediate + High (IS Int + High)
Number of subjects: 1322

Group type: EXPERIMENTAL
Intervention: mFOLFOX6 (6 months)
Number of subjects: 1322

Group type: COMPARATOR
Intervention: mFOLFOX6 (3 months)
Number of subjects: 1322
Study: 32294561

Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (400-800U)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA treatment for pes equinovarus
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA treatment
Number of subjects: 132
Study: 32295400

Group type: EXPERIMENTAL
Intervention: Migraine patients with ictal neck pain
Number of subjects: 100

Group type: COMPARATOR
Intervention: Migraine patients without ictal neck pain
Number of subjects: 100

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 100
Study: 32295455

Group type: EXPERIMENTAL
Intervention: Nellix Endoprosthesis
Number of subjects: 0
Study: 32295504

Group type: EXPERIMENTAL
Intervention: Intravenous recombinant tissue-type plasminogen activator
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Endovascular therapy
Number of subjects: 272

Group type: COMPARATOR
Intervention: Overall population
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Age <75 years
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Initial NIHSS score 0 to 3
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Blood glucose level ≤140 mg/dL
Number of subjects: 272
Study: 32295510

Group type: EXPERIMENTAL
Intervention: Onboard computed tomography angiography (CTA) with direct ET team notification
Number of subjects: 0

Group type: COMPARATOR
Intervention: No onboard CTA (historical control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Onboard CTA
Number of subjects: 0
Study: 32295774

Group type: EXPERIMENTAL
Intervention: Children with chronic conditions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 0
Study: 32295829

Group type: EXPERIMENTAL
Intervention: Pitavastatin calcium (4 mg/day) for 180 days
Number of subjects: 12
Study: 32296355

Group type: EXPERIMENTAL
Intervention: Paliperidone ER
Number of subjects: 120

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 120
Study: 32296711

Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation, dosage not specified, duration not specified
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 32296873

Group type: EXPERIMENTAL
Intervention: Ivosidenib 500-mg QD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ivosidenib
Number of subjects: 0
Study: 32296969

Group type: EXPERIMENTAL
Intervention: Global longitudinal strain (GLS) by cardiac magnetic resonance feature tracking (CMR-FT)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Addition of GLS to a baseline model comprising LVEF, infarct size, and microvascular obstruction
Number of subjects: 232
Study: 32297284

Group type: EXPERIMENTAL
Intervention: Pirfenidone
Number of subjects: 219
Study: 32297876

Group type: EXPERIMENTAL
Intervention: Postural garment (Posture Plus Force) worn for 2 to 4 hours per day for 90 days
Number of subjects: 32

Group type: COMPARATOR
Intervention: Physiotherapy sessions (5 sessions of 20 minutes each) for stretching and strengthening exercises, continued at home for 90 days
Number of subjects: 32
Study: 32297945

Group type: EXPERIMENTAL
Intervention: Treatment Expectation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0